Skip to content

Study on the effects of enhanced external counterpulsation therapy on cardiopulmonary function, arteriosclerosis and muscle strength in COPD patients

Study on the effects of enhanced external counterpulsation therapy on cardiopulmonary function, arteriosclerosis and muscle strength in COPD patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105442
Enrollment
Unknown
Registered
2025-07-03
Start date
2024-07-13
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Group of enhanced external counterpulsation:Enhanced external counterpulsation
Control group:No intervention

Sponsors

Qingdao Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Meets the GOLD grades I.-IV. of the Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2023 Revised Edition) for chronic obstructive pulmonary disease.

Exclusion criteria

Exclusion criteria: 1. Patients with coronary heart disease who have received enhanced external counterpulsation therapy for a long time; 2. various types of bleeding disorders may be or have existed; 3. After examination, there are infectious diseases, active thrombosis and active phlebitis and other diseases in both lower limbs; 4. Congenital heart disease, severe valvular heart disease, coronary artery recurrent, aortic or coronary artery aneurysm, arterial dissection, pulmonary embolism, severe pulmonary hypertension, etc.; 5. Patients with severe or frequent arrhythmias, such as atrial fibrillation, frequent atrial or ventricular premature contractions, etc., or rapid ventricular rate (heart rate>90 beats/min); 6. Severe or acute heart failure (NYHA grade IV), or LVEF value 170 mmHg and/or diastolic blood pressure > 110 mmHg); 8. Pregnant women; 9. Others: malignant tumors, acute severe infectious diseases, severe autoimmune diseases, severe organic diseases, etc.

Design outcomes

Primary

MeasureTime frame
6-minute walk test Pulmonary function tests;

Countries

China

Contacts

Public Contacthan wei

Qingdao Municipal Hospital

sallyhan1@163.com+86 532 8278 9053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026